Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Moderna, Inc. (MRNA : NSDQ)
 
 • Company Description   
Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency use in several countries as COVID-19 vaccine. The company has also developed booster doses of its COVID-19 vaccine and is developing variant-specific booster candidates.

Number of Employees: 4,700

 
 • Price / Volume Information   
Yesterday's Closing Price: $46.88 Daily Weekly Monthly
20 Day Moving Average: 8,070,514 shares
Shares Outstanding: 396.79 (millions)
Market Capitalization: $18,601.33 (millions)
Beta: 1.05
52 Week High: $59.55
52 Week Low: $22.28
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -11.30% -15.63%
12 Week -9.34% -16.19%
Year To Date 58.97% 47.34%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
325 BINNEY STREET
-
CAMBRIDGE,MA 02142
USA		 ph: 617-714-6500
fax: -		 ir@modernatx.com http://www.modernatx.com
 
 • General Corporate Information   
Officers
Stephane Bancel - Chief Executive Officer
Noubar B. Afeyan - Chairman
James M. Mock - Chief Financial Officer
Sandra Horning - Director
Elizabeth Nabel - Director

Peer Information
Moderna, Inc. (CORR.)
Moderna, Inc. (RSPI)
Moderna, Inc. (CGXP)
Moderna, Inc. (BGEN)
Moderna, Inc. (GTBP)
Moderna, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 60770K107
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/07/26
Share - Related Items
Shares Outstanding: 396.79
Most Recent Split Date: (:1)
Beta: 1.05
Market Capitalization: $18,601.33 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-2.03 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-6.74 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 20.33% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/07/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.51
Price/Cash Flow: -
Price / Sales: 8.36
EPS Growth
vs. Year Ago Period: 53.17%
vs. Previous Quarter: 44.08%
Sales Growth
vs. Year Ago Period: 260.19%
vs. Previous Quarter: -42.63%
ROE
03/31/26 - -26.64
12/31/25 - -30.15
09/30/25 - -29.81
ROA
03/31/26 - -19.32
12/31/25 - -22.95
09/30/25 - -23.20
Current Ratio
03/31/26 - 2.41
12/31/25 - 3.29
09/30/25 - 3.92
Quick Ratio
03/31/26 - 2.35
12/31/25 - 3.22
09/30/25 - 3.73
Operating Margin
03/31/26 - -104.14
12/31/25 - -145.16
09/30/25 - -132.53
Net Margin
03/31/26 - -143.55
12/31/25 - -145.16
09/30/25 - -139.61
Pre-Tax Margin
03/31/26 - -141.03
12/31/25 - -142.39
09/30/25 - -141.26
Book Value
03/31/26 - 18.67
12/31/25 - 22.14
09/30/25 - 23.89
Inventory Turnover
03/31/26 - 7.96
12/31/25 - 4.07
09/30/25 - 5.65
Debt-to-Equity
03/31/26 - 0.08
12/31/25 - 0.07
09/30/25 - 0.00
Debt-to-Capital
03/31/26 - 7.53
12/31/25 - 6.59
09/30/25 - 0.28
 

Powered by Zacks Investment Research ©